Future Outlook for Treatment of Endometrial Cancer
The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.
Read More
KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer
The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.
Read More
The PHAEDRA Study and Clinical Trial Landscape in Endometrial Cancer
A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.
Read More
MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer
Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.
Read More
Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer
A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.
Read More
Efficacy of Subsequent Therapies in Advanced Ovarian Cancer
Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.
Read More
Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer
A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.
Read More
Ovarian Cancer: Deciding Between Treatment Options
Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.
Read More
Frontline Maintenance Therapy in Ovarian Cancer
A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.
Read More
Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian Cancer
March 26th 2019Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses individualized dosing of niraparib in the treatment of patients with ovarian cancer.
Read More
Dr. Matulonis on the Use of Immunotherapy in Recurrent Ovarian Cancer
January 11th 2019Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the use of immunotherapy in patients with recurrent ovarian cancer.
Read More
Dr. Matulonis Discusses QoL Data from GOG-258 in Endometrial Cancer
August 17th 2018Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the quality-of-life outcomes from the GOG-258 trial in patients with endometrial cancer.
Read More
Dr. Matulonis Discusses Rationale of QUADRA Trial
July 24th 2018Ursula A. Matulonis, MD, chief, Division of Gynecological Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the rationale behind the QUADRA trial for patients with relapsed ovarian cancer.
Read More
Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian Cancer
March 26th 2018Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.
Read More